Abstract
Primary or acquired resistance to current treatment protocols remains a major concern in clinical oncology and may be caused by defects in apoptosis programs. Since recent data suggest that TRAIL can bypass apoptosis resistance caused by Bcl-2, we further investigated the role of Bcl-2 in TRAIL-induced apoptosis. Here we report that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma or breast carcinoma cell lines. Bcl-2 overexpression reduced TRAIL-induced cleavage of caspase-8 and Bid indicating that caspase-8 was activated upstream and also downstream of mitochondria in a feedback amplification loop. Importantly, Bcl-2 blocked cleavage of caspases-9, -7 and -3 into active subunits and cleavage of the caspase substrates DFF45 or PARP. Also, Bcl-2 blocked cleavage of XIAP and overexpression of XIAP conferred resistance against TRAIL indicating that apoptosis was also amplified through a feedforward loop between caspases and XIAP. In contrast, in SKW lymphoblastoid cells, TRAIL-induced activation of caspase-8 directly translated into full activation of caspases, cleavage of XIAP, DFF45 or PARP and apoptosis independent of Bcl-2 overexpression, although Bcl-2 similarly inhibited loss of mitochondrial membrane potential and the release of cytochrome c, AIF and Smac from mitochondria in all cell types. By demonstrating a cell type dependent regulation of the TRAIL signaling pathway at different level, e.g. by Bcl-2 and by XIAP, these findings may have important clinical implication. Thus, strategies targeting the molecular basis of resistance towards TRAIL may be necessary in some tumors for cancer therapy with TRAIL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berthold F, Burdach S, Kremens B, Lampert F, Niethammer D, Riehm H, Ritter J, Treuner J, Utsch S, Zieschang J . 1990 Klin. Pädiatr. 202: 262–269
Debatin KM . 1997 J. Natl. Cancer Inst. 89: 750–751
Deveraux QL, Reed JC . 1999 Genes Dev. 13: 239–252
Du C, Fang M, Li Y, Li L, Wang X . 2000 Cell 102: 33–42
Fels C, Schafer C, Huppe B, Bahn H, Heidecke V, Kramm CM, Lautenschlager C, Rainov NG . 2000 Neurooncol. 48: 207–216
Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . 1997 Cancer Res. 57: 3823–3829
Fulda S, Susin SA, Kroemer G, Debatin KM . 1998a Cancer Res. 58: 4453–4460
Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM . 1998b Cell Death Differ. 5: 884–893
Fulda S, Meyer E, Debatin KM . 2000 Cancer Res. 60: 3947–3956
Gazitt Y, Shaughnessy P, Montgomery W . 1999 Cytokine 11: 1010–1019
Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG . 1999 J. Biol. Chem. 274: 28379–28384
Hengartner MO . 2000 Nature 407: 770–776
Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H . 2000 Oncogene 19: 5477–5486
Hoehner JC, Hedborg F, Wiklund HJ, Olsen L, Pahlman S . 1995 Int. J. Cancer 62: 19–24
Holcik M, Korneluk RG . 2001 Nat. Rev. Mol. Cell. Biol. 2: 550–556
Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T . 2001 Nat. Med. 7: 954–960
Kaufmann SH, Earnshaw WC . 2000 Exp. Cell Res. 256: 42–49
Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ . 2000 FEBS Lett. 471: 93–98
Kim EJ, Suliman A, Lam A, Srivastava RK . 2001 Int. J. Onco. 18: 187–194
Kroemer G . 1997 Nat. Med. 3: 614–620
Kroemer G, Reed JC . 2000 Nat. Med. 6: 513–519
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A . 2001 Nat Med. 7: 383–385
Medema JP, Scaffidi C, Kischkel FC, Shevchenko ANJ, Mann M, Krammer PH, Peter ME . 1997 EMBO J. 16: 2794–2804
Mitsiades N, Vassiliki P, Tseleni-Balafouta S, Koutras DA, Stamenkovic I . 2000 Cancer Res. 60: 4122–4129
Nagane M, Huang HJ, Cavenee WK . 2001 Apoptosis 6: 191–197
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . 1991 J. Immunol. Meth. 139: 271–279
Peter ME, Krammer PH . 1998 Curr. Opin. Immunol. 10: 545–551
Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . 1998 FEBS Lett. 427: 124–128
Rokhlin OW, Guseva N, Tagiyev A, Knudson CM, Cohen MB . 2001 Oncogene 20: 2836–2843
Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A . 2000 Cancer Res. 60: 5673–5680
Sasaki H, Sheng Y, Kotsuji F, Tsang BK . 2000 Cancer Res. 60: 5659–5666
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME . 1998 Eur. J. Biochem. 254: 439–459
Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958
Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME . 1998 EMBO J. 17: 1675–1687
Slee EA, Adrain C, Martin SJ . 2001 J. Biol. Chem. 276: 7320–7326
Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ . 1999 J. Cell. Biol. 144: 281–292
Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . 2000 Immunity 12: 599–609
Suliman A, Lam A, Datta R, Srivastava RK . 2001 Oncogene 20: 2122–2133
Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS . 2001 Biochem. Biophys. Res. Commun. 280: 788–797
Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G . 1999 Nature 397: 441–446
Suzuki Y, Nakabayashi Y, Takahashi R . 2001 Proc. Natl. Acad. Sci. USA 98: 8662–8667
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH . 1999 Nat. Med. 5: 157–163
Walczak H, Bouchon A, Stahl H, Krammer PH . 2000 Cancer Res. 60: 3051–3057
Walczak H, Krammer PH . 2000 Exp. Cell Res. 256: 58–66
Wolf BB, Schuler M, Echeverri F, Green DR . 1999 J. Biol. Chem. 274: 30651–30656
Acknowledgements
We thank Petra Miller-Rostek for expert technical assistance, PH Krammer (DKFZ, Heidelberg, Germany) for anti-FLICE antibody, X Wang for anti-Smac antibody (University of Texas, Dallas, TX, USA), G Kroemer (CNRS, Villejuif, France) for anti-AIF antibody, JC Reed (Burnham Institute, San Diego, CA, USA) for XIAP cDNA plasmid, A Lopez-Rivas (University of Granada, Spain) for MCF-7 breast carcinoma and M Weller (University of Tuebingen, Germany) for LN-229 glioblastoma cells. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung and Technologie, Bonn, the Deutsche Leukämieforschungshilfe, the Wilhelm Sander-Stiftung and the European community.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fulda, S., Meyer, E. & Debatin, KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283–2294 (2002). https://doi.org/10.1038/sj.onc.1205258
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205258
Keywords
This article is cited by
-
4,8-Dicarboxyl-8,9-iridoid-1-glycoside inhibits apoptosis in human osteoarthritis chondrocytes via enhanced c-MYC-mediated cholesterol metabolism in vitro
Arthritis Research & Therapy (2023)
-
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
Cell Death & Differentiation (2023)
-
Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer
Apoptosis (2022)
-
Encephalitozoon intestinalis Infection Impacts the Expression of Apoptosis-Related Genes in U937 Macrophage Cells
Acta Parasitologica (2021)
-
IgG-single-chain TRAIL fusion proteins for tumour therapy
Scientific Reports (2018)